Help paying · Medicare negotiated price · pharmacy cost · cycle 2028
Cosentyx (secukinumab): where help paying exists, where Medicare's negotiation stands and what pharmacies pay
1 assistance program lists secukinumab, each with its income ceiling and when we read it. CMS has selected Cosentyx for the 2028 negotiation cycle. The CMS file we read (November 6, 2026) lists its negotiated price as taking effect January 1, 2028 and holds no price for it yet, so this page shows no negotiated price. 8 non-manufacturing label changes are dated in the last 12 months in the FDA's file. The FDA's enforcement reports name this drug's packages in 1 recall entry. ClinicalTrials.gov lists 11 recruiting trials that name secukinumab.
Every package CMS lists
Packages the CMS file lists for Cosentyx, with NADAC per unit where the benchmark has one (per unit, as the files state).
| NDC | Product | Unit | CMS price status | NADAC |
|---|---|---|---|---|
| 00078-0639-41 | COSENTYX SYRINGE 150MG/ML 2 SENSOREADY | ML | Selected; price takes effect January 1, 2028, not yet published | $3,946 |
| 00078-0639-68 | COSENTYX SYRINGE 150MG/ML SENSOREADYPEN | ML | Selected; price takes effect January 1, 2028, not yet published | $7,858 |
| 00078-0639-97 | COSENTYX SYRINGE 150MG/ML | ML | Selected; price takes effect January 1, 2028, not yet published | $7,888 |
| 00078-0639-98 | COSENTYX SYRINGE 150MG/ML 2 | ML | Selected; price takes effect January 1, 2028, not yet published | $3,929 |
| 00078-1056-97 | (name not listed) | n/a | Selected; price takes effect January 1, 2028, not yet published | n/a |
| 00078-1070-68 | COSENTYX UNOREADY PEN 300MG/2ML | ML | Selected; price takes effect January 1, 2028, not yet published | $4,089 |
| 00078-1168-61 | (name not listed) | n/a | Selected; price takes effect January 1, 2028, not yet published | n/a |
Medicare Part D spending
CMS's Medicare Part D spending dataset reports gross spending on Cosentyx of $1.13 million in 2024, across 258 claims and 60 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
| Year | Gross spending | Claims | Beneficiaries | Average spending per claim |
|---|---|---|---|---|
| 2024 | $1.13 million | 258 | 60 | $4,393 |
Source: CMS Medicare Part D spending by drug (data-year-2024, modified 2026-06-25), read November 7, 2026. CMS dataset page. All manufacturers combined; the figures are a drug-level aggregate of claims and say nothing about a formulary or coverage.
Medicare Part B payment limit
CMS publishes a quarterly payment limit for the HCPCS code that its NDC crosswalk links to Cosentyx. It is a ceiling for providers who bill Medicare Part B, not a price a patient pays, and a code's presence says nothing about whether Medicare covers a product.
| HCPCS code | Quarter | Payment limit | Per dosage descriptor | Effective | Read |
|---|---|---|---|---|---|
| J3247 | 2026 Q4 | $18.13 | 1 MG | October 1, 2026 through December 31, 2026 | November 7, 2026 |
Source: CMS ASP pricing files (october-2026-medicare-part-b-payment-limit-files-final.zip and the matching NDC-HCPCS crosswalk). CMS ASP pricing files page.
Biosimilar status
- Cosentyx (secukinumab) is a reference product in the FDA Purple Book (BLA 125504, approved January 21, 2015). The Purple Book lists 0 biosimilars and 0 interchangeable products that name it as their reference product.
- Cosentyx (secukinumab) is a reference product in the FDA Purple Book (BLA 761349, approved October 6, 2023). The Purple Book lists 0 biosimilars and 0 interchangeable products that name it as their reference product.
This is what the FDA Purple Book lists on the read date. It is a record, not a forecast of when any product will launch or be substituted.
Source: FDA Purple Book (purplebook-2026-10), read November 7, 2026. Purple Book data file.
Rare-disease (orphan) designations
The FDA's orphan drug database lists 1 designation for secukinumab. A designation is not an approval and not a statement that the drug treats the condition; the status column is the database's own.
| Designated | Designated use | Status | Sponsor |
|---|---|---|---|
| March 26, 2010 | Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression | Designated/Designation Withdrawn or Revoked | Novartis Pharmaceutical Corporation |
Source: FDA Orphan Drug Designations and Approvals database, read November 7, 2026. FDA orphan drug search.
Medicaid use by state
CMS's State Drug Utilization Data records, for 2025, how many prescriptions each state's Medicaid program paid for under this drug's packages and what it reimbursed. The 10 states with the largest reimbursement are shown of 26 with data. Reimbursement is before the rebates manufacturers pay states, so it is not a net cost and not a price a patient pays.
| State | Medicaid-paid prescriptions | Medicaid reimbursed | Covers |
|---|---|---|---|
| OH | 2,143 | $21,192,403 | Fee-for-service only |
| LA | 1,007 | $10,856,150 | Fee-for-service only |
| MO | 434 | $4,907,725 | All record types |
| UT | 210 | $2,194,197 | All record types |
| SD | 137 | $1,482,838 | All record types |
| VT | 115 | $1,233,829 | All record types |
| IL | 135 | $1,145,280 | All record types |
| DC | 76 | $1,052,444 | All record types |
| MN | 213 | $832,467 | Fee-for-service only |
| NV | 77 | $563,920 | Fee-for-service only |
Where the publisher suppresses small managed-care cells, a state's figure covers fee-for-service claims only and understates use (11 state and package figures are marked that way here). A state missing from the table means its figures were suppressed or not reported, not zero use. 180 older-year figures are held and left out of the table.
Source: CMS State Drug Utilization Data (State Drug Utilization Data 2025, modified 2026-07-13T15:28:32Z), read November 7, 2026. CMS dataset page. State-reported data compiled by CMS; aggregate by state and package, no provider or patient data.
Where help paying exists
Offers the program pages state
- Manufacturer offer
The Cosentyx support page states a Bridge Program (Covered Until You Are Covered) that can provide up to 2 years of Cosentyx Subcutaneous Injection for free while coverage is sought, or until insurance approval if earlier, with conditions stated on the page.
Read November 7, 2026; quote matched against the saved page text.
Programs in our finder that list secukinumab. Each shows its income ceiling, when we read it and whether we checked it against the program's own document. Eligibility is decided by the program, not by us.
- Novartis Patient Assistance Foundation manufacturer
Income at or below $63,840 for one person, $86,560 for two (NPAF eligibility tool, read 13 October 2026)Status. The Novartis Patient Assistance Foundation page states that for patients who applied for NPAF support on or after July 27, 2026, a new Patient Enrollment Portal is used: approved patients are encouraged to use it to re-fill medication, and patients told their application is missing information are encouraged to upload documents through it. The page lists no end date. (read November 7, 2026)
Check where your income sits against each ceiling: open the assistance finder. See what has changed and when we last verified each program on the program status board.
Label changes
FDA actions on the applications behind Cosentyx dated since November 11, 2025, leaving out manufacturing (CMC) changes. 8 changes in the window.
| Date | Class | Application | Submissions | FDA documents |
|---|---|---|---|---|
| October 15, 2026 | Labeling | BLA125504 | 99 | Label (PDF) posted October 20, 2026 |
| October 15, 2026 | Efficacy | BLA761349 | 13 | Label (PDF) posted October 20, 2026FDA letter posted October 16, 2026 |
| April 17, 2026 | Efficacy | BLA125504 | 98 | Label (PDF) posted April 21, 2026FDA letter posted April 20, 2026 |
| April 17, 2026 | Efficacy | BLA125504 | 97 | Label (PDF) posted April 21, 2026FDA letter posted April 20, 2026 |
| April 17, 2026 | Labeling | BLA761349 | 12 | Label (PDF) posted August 26, 2026FDA letter posted April 20, 2026 |
| April 17, 2026 | Labeling | BLA761349 | 11 | Label (PDF) posted April 21, 2026FDA letter posted April 20, 2026 |
| March 12, 2026 | Efficacy | BLA125504 | 91 | Label (PDF) posted August 26, 2026FDA letter posted March 16, 2026 |
| March 12, 2026 | Labeling | BLA761349 | 10 | Label (PDF) posted August 26, 2026FDA letter posted March 16, 2026 |
Source: FDA Drugs@FDA data file, read November 7, 2026. Dates are the FDA action dates; the documents are on FDA's own site. FDA data file. All recent changes across these drugs: label changes feed.
Safety notices
FDA enforcement report entries that name a package of Cosentyx by its NDC: 1 entry, newest first. FDA assigns each a class by health risk: Class I is the most serious and Class III the least. An entry records what the recalling firm reported and FDA classified; it is not advice about any package you hold.
| Reported | Class | Status | Recalling firm | Reason (shortened) | Packages named |
|---|---|---|---|---|---|
| May 16, 2018D-0742-2018 | Class II | Terminated | Kroger Specialty Pharmacy, Inc. | Lack of Processing Controls. | 1 |
Source: openFDA drug enforcement reports, file read November 7, 2026. openFDA data file. All recent recalls across these drugs: drug recalls feed.
Clinical trials recruiting
ClinicalTrials.gov lists 11 interventional trials that name secukinumab and are recruiting, and 10 more not yet recruiting. By phase: Phase 4: 5, Not applicable: 3, Phase 1: 2, Phase 2: 1. The 10 most recently updated are below. A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
| Trial | Title and conditions | Phase | Lead sponsor | Last updated | Countries |
|---|---|---|---|---|---|
| NCT07237594 | IL-17 Blockade to Decrease irAEs (REPLAY)Metastatic Melanoma | Phase 1 | Duke University | November 6, 2026 | United States |
| NCT06751238 | Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).Juvenile Psoriatic Arthritis | Phase 1 | Novartis Pharmaceuticals | October 13, 2026 | United States |
| NCT04638647 | Secukinumab Open Label Roll-over Extension ProtocolAutoimmunity, Inflammation | Phase 4 | Novartis Pharmaceuticals | October 13, 2026 | United States, Brazil, Bulgaria and 7 more |
| NCT07489573 | Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativa (HS) | Phase 4 | Novartis Pharmaceuticals | September 9, 2026 | China |
| NCT06399432 | Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 InhibitorsPsoriasis | Not applicable | University Hospitals Cleveland Medical Center | September 4, 2026 | United States |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRheumatic Disease | Phase 2 | NYU Langone Health | July 9, 2026 | United States |
| NCT06398106 | Proactive TDM Versus Standard Use of Biologics in PsoriasisPsoriasis Vulgaris | Phase 4 | University Hospital, Ghent | March 4, 2026 | Belgium |
| NCT05303285 | A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing SpondylitisAnkylosing Spondylitis (AS) | Phase 4 | Tongji Hospital | January 27, 2026 | China |
| NCT07149792 | A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular BiomarkersPsoriasis; Psoriasis Arthritis; Biologics | Phase 4 | Taichung Veterans General Hospital | September 2, 2025 | Taiwan |
| NCT06707246 | A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese PatientsHidradenitis Suppurativa | Not applicable | Second Affiliated Hospital, Zhejiang University, School of Medicine | November 27, 2024 | China |
Source: ClinicalTrials.gov, registry data processed November 6, 2026, summarized and trimmed by OmniRx. Search on ClinicalTrials.gov.
Questions
What is the Medicare negotiated price of Cosentyx?
CMS has selected Cosentyx for the 2028 negotiation cycle. The CMS file we read (November 6, 2026) lists its negotiated price as taking effect January 1, 2028 and holds no price for it yet, so this page shows no negotiated price. When CMS publishes a price it will be a Medicare Part D price agreed with the manufacturer, not what a person pays at the counter.
How does the negotiated price compare with what pharmacies pay?
No negotiated price is published yet, so there is nothing to compare with the pharmacy acquisition benchmark.
Is there help paying for Cosentyx?
1 assistance program lists it in our finder. Eligibility depends on income, coverage and the program's current rules; each program's own page decides.
Can I join a clinical trial for Cosentyx?
ClinicalTrials.gov lists 11 recruiting interventional trials that name secukinumab (registry data processed November 6, 2026). A listing is not an offer of free drug and not medical advice. Whether a trial fits is decided by the study team and your own clinician.
How much does Medicare Part D spend on Cosentyx?
CMS's Medicare Part D spending dataset reports gross spending on Cosentyx of $1.13 million in 2024, across 258 claims and 60 beneficiaries. CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions. Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.
For developers: this drug as data
One call returns price, generic-entry upper bound, label history, recalls, trials, assistance, and where facts exist the FDA safety program (REMS), DEA schedule, orphan designations, safety notices and Medicaid use by state, each with receipts.
Example file: https://omnirx.org/api/v1/dossier/cosentyx.json
The licence page sets out what a data licence covers, and the API page documents these files.
Evaluation files with receipts; contract may change; not clinical advice.
Sources and terms. CMS Medicare Drug Price Negotiation Program data file (read November 6, 2026; the CMS page states no licence or restriction); CMS NADAC from data.medicaid.gov under the labels in the OmniRx licence ledger; program details read from each program's own pages; CMS Medicare Part D spending by drug; CMS ASP pricing files; FDA Purple Book; FDA Drugs@FDA and Orange Book data files; openFDA drug enforcement reports; ClinicalTrials.gov registry data. Figures are stored with their sources in the OmniRx library (edition 2026-11). Free to cite with attribution. Not medical, legal or financial advice. Report an error through the contact page. Licence the data.